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Abstract
Backgrounds: Intra-abdominal placement of the Central Venous Catheter (CVC) was conducted to manage the
ascites-related symptoms of non-ovarian cancer patients. The aim of this study is to document the efficacy of
symptom relief and conduct survival analysis of non-ovarian cancer patients with malignant ascites who received
paracentesis and indwelling catheter drainage.
Methods: Seventy eight patients received paracentesis and drainage. All patients who met the inclusion criteria
were included in this study. The overall survival (OS) was defined as the interval between initial diagnosis and
death. Since-paracentesis survival (SP-Survival) was defined as the interval between initial paracentesis and death.
Results: Hepatic cancer was the most frequent original cancer in this study. Peritoneal catheters remained in situ
for a median of 13 days. No immediate complications, such as perforation of a viscus or excessive bleeding, were
encountered during placement. All ascites-related symptoms improved after drainage compared with the baseline.
There was a statistically significant improvement in the mean score for abdominal swelling (p < 0.001), anorexia
(p = 0.023) and constipation (p = 0.045). Cancer type was shown to be an independent prognostic factor for
overall survival length (p = 0.001). Serum albumin was an independent prognostic factor for SP-survival (p = 0.02).
Conclusions: Paracentesis and indwelling catheter drainage through CVC set is a useful method for improving
painful symptom. Further research is needed to validate the findings.
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Background
Malignant ascites (MA) is defined as abnormal accumula-
tion of fluid within the peritoneal cavity caused by the
intraperitoneal spread of original cancer [1]. It accounts
for 10 % of all cases of ascites. 6 % of all admitted palliative
care patients receive treatment for MA [2].
MA is usually a sign of end-stage illness that is accom-
planied by abdominal pain, discomfort, anorexia, nausea,
and dyspnea. These ascites-related symptoms seriously
affect patients’ quality of life (QOL) [3, 4]. Except for ovar-
ian cancer, MA confers a poor prognosis, with a median
survival time of 5.7 months [5]. For gastrointestinal cancer
patients with MA, the median overall survival (OS) is less
than 3 months [6]. Therefore the therapy for advanced
non-ovarian cancer patients with MA is generally aimed
at managing ascites-related symptoms [7], alleviating
patients’ sufferings, and improving their QOL [8–10].
Limited treatment options exist for advanced cancer pa-
tients with MA. These patients not only have poor general
status but also respond poorly to dietary sodium restric-
tion and diuretics [11, 12]. Effective palliation of MA
remains a challenge [13]. Paracentesis and drainage are
widely performed for patients with MA whose considered
therapeutic goal is palliation [14, 15]. However, the effect
of paracentesis is short-lived and has to be repeated every
10 days on average [16]. Continuous peritoneal drain-
age through an indwelling catheter has been reported
to be hugely beneficial to symptom management,
* Correspondence: wenwucheng@yahoo.com
1Department of Integrated Therapy, Fudan University Shanghai Cancer
Center, Shanghai 200032, China
2Department of Oncology, Shanghai Medical College, Fudan University,
Shanghai 200032, China
Full list of author information is available at the end of the article
© 2016 Gu et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Gu et al. BMC Palliative Care  (2016) 15:44 
DOI 10.1186/s12904-016-0116-5
avoiding the hazards and disadvantages-direct and indirect
complications-of multiple repeated procedures [17, 18].
Although placement of indwelling catheters for symp-
tom relief has been a recommended therapy for end-stage
patients with MA, there is scant data in the existing litera-
ture that documents the efficacy of symptom relief and in-
cludes follow-up survival analysis [19, 20]. We conducted
a retrospective review of all non-ovarian cancer patients
who received indwelling catheters for the management of
symptomatic MA over a 3-year period. Considering the
different biomedical behaviors and therapeutic responses
of patients with ovarian cancer and MA [21–23], ovarian
cancer patients were excluded from this study. The aim of
this study is to document the efficacy of symptom relief
and to conduct a survival analysis of non-ovarian cancer




From March 2008 to March 2011, 345 cancer patients
were admitted to the Integrated Therapy Department
(also known as Palliative Care Unit, PCU) of Fudan Uni-
versity Shanghai Cancer Center (FUSCC). 145 patients
were diagnosed with MA. The inclusion criteria con-
sisted of the following: 1. Patients’ age was not less than
18 years at the time of enrollment. 2. Patients had histo-
logic or cytologic proof of original malignancy and/or
MA. 3. Patients had no chance to receive anti-cancer
treatments for malignancy, including systematic chemo-
therapy, radiotherapy and etc. 4. Patients received intra-
peritoneal catheterization and drainage during the interval
to relieve symptom sufferings. 5. A coagulation screen,
comprised of platelet count, prothrombin time (PT) and
activated partial thromboplastin time (aPTT), was per-
formed prior to the procedure to exclude contraindica-
tions. Of the 145 patients diagnosed with MA, 78 patients
met the inclusion criteria and were included in this
study. The international Classification of Disease-9 (ICD-9)
coding system was used to code the medical records
of all patients.
Medical records were reviewed by three attending
physicians through the Union Medical System (UMS) of
FUSCC to gather general characteristics, cancer-related
information, symptoms, and ascites-related records. The
UMS is the electronic medical records system containing
all the medical information of patients in the FUSCC,
including demographic and clinical data.
Catheter insertion procedure
Informed consent for paracentesis and drainage was ob-
tained before the procedure was performed. The proced-
ure was carried out by patients’ attending physicians with
more than 5 years’ clinical experience bedside with the
patient supine. Patients were asked to urinate before the
procedure. The CVC set used (Arrow Raulerson Syring,
USA, REF ES-04306), which contains multiple side-holes
in addition to an end-hole, was initially developed for deep
vein indwelling and allowed for improved drainage and
decreased risk of catheter blockage. The puncture site was
located by ultrasonographic imaging prior to the proced-
ure. 5–10 ml 2 % lidocaine was used for local anesthesia.
An introducer needle was inserted into the peritoneal cav-
ity, and a spring wire guide was placed in the peritoneal
cavity through the introducer needle. The needle was then
extracted. The indwelling catheter was placed in the peri-
toneal cavity following the spring wire guide after the ab-
dominal wall was dilated. The spring wire guide was then
extracted gradually with the catheter pushing forward into
the peritoneal cavity. The catheter outlet was attached to a
Heparin Cap (Heatlth Care Ltd) and a governor (part of
the Infusion Sets with Precision Filters for Single Use,
Wuhan W.E.O. Science&Technique Development Co,
Ltd), then connected to a drainage bag (Fig. 1). Finally, the
catheter was fixed to the abdominal wall by Statlock
(Catheter Stabilization Device, Bard Access Systems, Inc).
The governor for intravenous infusion was used to help
control the rate of fluid removal and prevent sudden rapid
fluid loss (Fig. 2). Especially for patients with tense ascites,
the high tension in the peritoneal cavity can result in rapid
drainage. We controlled the rate at about 300 ml per hour
(85drops/min) for patients. 1000–1500 ml ascites were as-
pirated on the first day. The fluid of the first day was used
for biochemical tests and fluid cytology. Drainage was
continued or stopped according to the patients’ suffering
and specific situation. Drainage was discontinued if dis-
ease progression or intolerable toxicities were confirmed





Fig. 1 The catheter insertion procedure. a A spring wire guide was
introduced into peritoneal cavity through the introducer needle.
b The indwelling catheter was put into the peritoneal cavity following
the spring wire guide after the abdominal wall was dilated. c The
spring wire guide was extracted gradually with the catheter pushing
forward into the peritoneal cavity. d The catheter outlet attached to a
Heparin Cap and a governor
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hypovolemia and paracentesis-induced circulatory dys-
function (PICD), infusion of albumin and synthetic plasma
expanders was used for all patients during the drainage
interval. The diuretics were used and adjusted according
to patients’ weight loss and electrolyte levels. The volume
of extracted ascites and immediate and late complications
including hypotension, haemorrhage, tube blockage, dis-
lodgment and sepsis, were recorded in chart.
Evaluation
The symptoms related with ascites were assessed before
paracentesis and then at the end-point of catheter
removal. The most frequent ascites-related symptoms in-
cluded fatigue, abdominal swelling, anorexia, abdominal
pain, constipation, dyspnea, nausea and vomiting, insom-
nia, early satiety, and dizziness. The severity of the symp-
toms was assessed on a scale from 0 to 10, with zero
denoting no symptom sufferings and ten representing
symptoms as severe as the patients could imagine. The
mean score of ascites-related symptoms was calculated
and pre- and post-treatment scores were compared. Pa-
tient data was retrospectively reviewed through the charts.
Patient follow up took place 1 week after discharge and
monthly for 6 months, then once every 3 months until
death. The data were obtained from phone call records
of the follow-up information of the Department. The
overall survival (OS) was defined as the interval post-
disease diagnosis till death (months). Since-paracentesis
survival (SP-survival) was defined as the interval post-
initial paracentesis till death (days).
Statistical analysis
Continuous variables were compared using the t-test for
samples, while frequencies and rates were compared
using the chi-square test. Symptom scores were pre-
sented as mean ± standard error. Pre-and post-treatment
symptom scores were compared using a t-test. Values of
p < 0.05 were considered to be statistically significant.
The relationship between each variable and survival time
was analyzed by the Kaplan-Meier method and Cox pro-
portional hazards models. Statistical analysis was per-
formed using Statistical Package for the Social Sciences




During the study period, 178 patients were diagnosed
with MA. Eighty two non-ovarian cancer patients ac-
cepted paracentesis and indwelling catheter drainage.
Seventy eight patients were eligible for this study, with
43 male and 35 females. The mean age of those included
was 58 years old (95 % CI: 55–62). The most frequent
original cancers causing ascites in this study were hep-
atic (15, 19.2 %), pancreatic (12, 15.4 %) and colorectal
cancer (12, 15.4 %). 59 (75.6 %) patients had visceral me-
tastasis. The liver (59.0 %) was the most prevalent meta-
static site, and 38 patients (48.7 %) had more than three
sites of metastasis. 33 (42.3 %) patients were also diag-
nosed with pleural effusion. Thirty four patients had pre-
viously received chemotherapy, with a median of three
previous courses of chemotherapy. The most frequent
KPS was 40, indicating that patients were mainly bed
bound, needing assistance with care.
Insertion of the catheter was technically successful in
all 78 cases. 16 patients had two catheters inserted in
separated locations. The peritoneal catheters remained
in situ for a median of 13 days (range 5–18 days).
The mean depth of the ascites before drainage scanned by
B-type ultrasound was 93.6 mm (range: 35–143). The
medial total serum albumin at admission was 30.1 g/L
(range: 21–36). The median volumeof drainages per pa-
tient was 5750 ml and the mean volume was 8538 ml
(range: 750–53300 ml). Diuretics were used in 70 patients
concomitant with the paracentesis. Among these patients,
35 patients used spironolactone alone, ten used furosem-
ide alone, and 25 patients used both.
No immediate complication such as perforation of a
viscus or excessive bleeding was encountered during the
placement procedure. Seven patients had continuous
leakage of peritoneal fluid from the needle site during
the drainage. The general characteristics and ascites-
related characteristic are shown in Table 1.
Symptom improvement after drainage
The most common symptom before paracentesis was fa-
tigue, reported in 73 patients (93.6 %). The second most
common symptom was abdominal swelling in 72 patients
(92.3 %), then anorexia in 59 (75.6 %), and abdominal pain
in 36 (46.2 %) patients. For 62 patients, more than 3
symptoms were reported. All the ascites-related symptoms
were alleviated after drainage compared with the baseline.
There was a statistically significant alleviation in the
a b
Fig. 2 The indwelling catheter and drainage governor. a The catheter
was fixed to abdominal wall by Statlock; b The governor for intravenous
infusion was used to help control the rate of fluid removal
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mean score for abdominal swelling (p < 0.001), an-
orexia (p = 0.023) and constipation (p = 0.045). Details
are shown in Table 2.
Post-drainage survival outcomes
Follow-up was conducted until death or at the time of
the study (December, 2013). Fourteen patients received
indwelling catheter drainage twice. Seventy patients died
within the follow-up period and 8 patients were still
alive at the time of survival analysis. The median OS was
13 months (95 % CI: 11.2–14.8). Patients with ascites of
gastrointestinal origin group had the worst OS (p = 0.001)
(Fig. 3a, b). The median SP-Survival was 36 days (95 % CI:
29.9–43.0). Serum albumin concentration significantly
affected survival with a serum albumin of greater than
30 g/L being associated with an improved SP-Survival
(p = 0.02) (Fig. 3c, d). Multivariate Cox regression
showed cancer type to be an independent prognostic
factor for OS and serum albumin to be an independent
prognostic factor for SP-Survival. Details are shown in
Table 3.
Discussion
The mechanism of production of MA is a complex, multi-
factorial process [24]. No validated guidelines for prevent-
ing or reducing the production reaccumulation of MA
currently exist [25]. Though indwelling peritoneal drain-
age catheters were considered to be the first choice for pa-
tients with MA who received palliative care [26], there
were no international standards or guidelines for paracen-
tesis and drainage, or specially designed catheters for con-
tinuous peritoneal drainage [27]. Previous studies
reported the successful use of many different catheters for
refractory ascites [28, 29]. At first, the CVC set was not
used for abdominal paracentesis. Previous studies testified
its safety, convenience and fewer complications for intra-
peritoneal chemotherapy in advanced gastric cancer [30].
Table 1 Seventy-eight patients’ general and ascites related characteristics (N = 78)
General characteristics N. % Ascites related N %
Age Serum albumin(g/L)
<=50 21 26.9 <=30 32 41.0
50–70 43 55.1 >30 46 59.0
> = 70 14 17.9 Color
Gender Yellow 15 19.2
Male 35 44.9 Brown 43 55.1
Female 43 55.1 Red 20 25.6
Malignancy type Gravity
GI groupa 48 61.5 >1.012 23 29.5
Othersb 16 20.5 <=1.012 55 70.5
Unknown 14 17.9 Rivalta test
Metastasis - 22 28.2
Liver 46 59.0 + 47 60.2
Lung 16 20.5 (++ − +++) 9 11.5
Bone 12 15.4 Ascites LDH
Treatment History >200 45 57.7
Surgery 33 42.3 <=200 33 42.3
Chemotherapy 35 44.9 Removed ascites volume
Radiotherapy 35 44.9 <=3000 ml 16 20.5
Others 22 28.2 3000–5000 ml 25 32.1
Diuretics > = 5000 ml 37 47.4
Aldosterone antagonist only 35 44.9
Frusemide only 10 12.8
Combination of both 25 32.1
Rivalta Test The Rivalta test was used in order to differentiate a transudate from an exudate. A positive the test meant high protein concentration of ascite fluid
and possibly a relationship with Spontaneous bacterial peritonitis (SBP)
Ascites LDH Ascites lactate dehydrogenase was used to differentiate malignant transudate from benign transudate
aGI group: The gastrointestinal group included hepatic cancer, pancreatic cancer, colorectal cancer and etc
bOther primary tumors included lung, breast, renal, etc. Unknown is for patients that had malignant proof but not primary proof
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Table 2 The most frequent ascites related symptoms and change post- paracentesis
Symptoms N % Medina score before drainage Mean score before drainage Mean score After drainage p Value
Fatigue 73 93.6 6 6.7 6.4 >0.05
Abdominal swelling 72 92.3 7 5.3 2.4 <0.001*
Anorexia 59 75.6 7 6.2 4.7 =0.023*
Abdominal pain 36 46.2 5 4.5 2.1 >0.05
Constipation 29 37.1 6 5.6 4.5 0.045*
Dyspnea 26 33.3 4 3.2 2.5 >0.05
Nausea &vomiting 18 23.1 5 4.6 3.7 >0.05
Insomnia 30 38.5 4 4.2 2.5 >0.05
Early satiety 10 12.8 4 3.8 3.6 >0.05
dizzy 4 5.1 4 4.5 3.4 >0.05
The pre-paracentesis and post-paracentesis scores of the symptoms assessment were compared using a t test of the mean scores
* p < 0.05
Fig. 3 a The median overall survival (survival since diagnosis) was 13 months (95 % CI: 11.2–14.8). b patients with ascites of GI origin group had
the worst overall survival (p = 0.001). c The median survival from paracentesis and indwelling catheter drainage (SP-Survival) was 36 days (95 % CI:
29.9–43.0). d Serum albumin concentration significantly affected survival with a normal serum albumin of greater than 30 g/L being associated
with an improved SP-Survival (p = 0.02)
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In our department, the CVC set for Seldinger technique
was used. This technique has been successfully applied for
8 years in our department. This retrospective study dem-
onstrated that subcutaneous peritoneal indwelling cathe-
ters through CVC were safe, feasible, and effective for
terminally ill cancer patients with MA.
The CVC used as the indwelling catheter offered lots of
potential advantages. The technique is a simple method
that can be performed by both trained physicians and in-
ternal medicine residents. Whereas some other methods
are more invasive and require an operating room, this
procedure can be performed at the bedside. [31]. Less im-
mediate complications, such as perforation of a viscus or
excessive bleeding, were encountered during the catheter
insertion, drainage and catheter extraction. The short
placement of the catheter obviously decreased the
catheter-induced peritonitis that is normally caused by the
catheter remaining in the patient for long periods of time
[32, 33]. Further studies to investigate the use of CVC on
patient outcomes should be conducted.
It had been suggested that reducing the flow rate of asci-
tes extraction may help to prevent PICD [34]. Use of the
governor allowed for the drainage rate to be controlled ac-
cording to patients' condition and blood pressure. The
drainage volume can be adjusted from a few litres to a
maximum of over 20 L. In order to further guarantee the
safety of this technique, intravenous infusions were ad-
ministered to avoid negative effects like hypovolemia. Al-
bumin infusion was used routely for these patients. The
albumin infusion increased invascular oncotic pressure
and caused mobilization of fluids from the interstitium
into the intravascular space. Some studies showed that the
recurrence of ascites decreased for patients with good di-
uretic response when combined with albumin. Previous
studies reported that albumin infusion reduced the
incidence of post-paracentesis circulatory dysfunction by
Table 3 Multivariate analysis of overall survival and SP-Survival by Cox proportional hazards models
Variables Overall Survival SP Survival
p Hazard Ratio(95 % CI) p Hazard Ratio(95 % CI)
Age 0.681 0.656
<=50 Ref Ref Ref
50–70 0.575 1.211 (0.621–2.361) 0.360 1.357(0.707–2.604)
> = 70 0.744 0.858 (0.344–2.140) 0.617 1.246(0.526–2.950)
Gender(male/female) 0.323 1.339 (0.750–2.392) 0.667 0.877(0.484–1.591)
Primary cancer 0.026* 0.315
GI group Ref Ref Ref Ref
Others 0.03 0.418 (0.190–0.920) 0.561 0.805(0.388–1.672)
Unknown 0.033 0.423 (0.192–0.932) 0.134 0.566(0.268–1.192)
Ascites related
Color 0.566 0.693
Yellow Ref Ref Ref Ref
Brown 0.291 1.571 (0.680–3.630) 0.543 0.779(0.348–1.742)
Red 0.656 1.167 (0.591–2.304) 0.830 1.074(0.561–2.054)
LDH (>200/<=200) 0.225 0.798 (0.442–2.350) 0.065 0.520(0.275–0.984)
Rivalta Test 0.077 0.745
- Ref Ref Ref Ref
+ 0.067 0.258 (0.096–0.695) 0.453 1.418(0.570–3.530)
++ − +++ 0.088 0.357 (0.141–0.902) 0.507 1.321(0.581–3.003)
Gravity (>1.012/<=1.012) 0.260 0.706 (0.385–1.294) 0.159 0.649(0.356–1.185)
Volume removed 0.904 0.357
<=3000 ml Ref Ref Ref Ref
3000–5000 ml 0.701 1.161 (0.542–2.484) 0.873 0.939(0.433–2.035)
> = 5000 ml 0.961 0.985 (0.537–1.806) 0.249 1.494(0.755–2.958)
Serum albumin (<30 g/L/> = 30 g/L) 0.394 0.759 (0.402–1.432) <0.001* 0.258(0.128–0.517)
Primary cancer diagnosis had a significant relationship with the overall survival (p= 0.026). The serum albumin level had a significant relationship with SP-Survival (p< 0.001)
*p < 0.05
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15–20 % [35]. However, controversy still existed for albu-
min infusion for refractory ascites [36]. One study demon-
strated that only 11 % of the oncologists in a previous
survey used human albumin when patients received para-
centesis and drainage [37].
Previous study have reported that apart from ovarian
cancer, gastrointestinal cancer was the most common
tumor of origin [38], with up to 15 % of all patients with
gastrointestinal cancers developing ascites at some stage
of their disease [39]. In our study, hepatic cancer had the
highest proportion. This may be due to the high incidence
of primary hepatocellular carcinoma in the population of
mainland China. The percentage of unknown original
tumors was 17.9 %, similar with the 20 % of all patients
with MA in previous studies [40].
Non-resolving or recurrent MA was always considered
to be associated with poor survival [41]. However, the
prognostic factors associated with MA had been poorly
studied. One study that focused on pancreatic cancer
testified that ascites was a harbinger of the final stage of
pancreatic cancer and the median survival after ascites
occurred was usually between 2 to 4 months [42]. An-
other retrospective review of 76 patients with MA
demonstrated that the median survival following ascites
diagnosis was 2.25 months. In our research, the survival
since ascites occurred was not analyzed because the
retrospective method did not allow for precise determin-
ation of the date of ascites diagnosis. Our research fo-
cused on survival since original cancer diagnosis and
survival since paracentesis, which also reflected that pa-
tients with MA were associated with minimal remaining
life expectancy. The unknown original group had a bet-
ter survival than GI origin group in this study. One po-
tential explanation might be that we could not exclude
some ovarian cancer patients from the unknown original
group, as some ovarian cancer cannot be diagnosed des-
pite together with MA. These patients may resulted in
the unknown original group had a better survival in this
research.
Although the usage of albumin is still controversial,
previous studies testified that the a low level of serum al-
bumin was an independent prognostic factor adversely
affecting survival for non-ovarian cancer patients with
MA [43, 44]. In this study, patients in the low level
serum albumin group had poorer prognoses, and the
median survival since paracentesis for this group was
only 35 days. The low serum albumin concentration was
always accompanied by liver dysfunction and poor pro-
tein concentrations. Prospective research focused on the
effectiveness of albumin infusion and relationships with
the serum albumin concentration of these patients needs
to be conducted.
Symptoms related to refractory ascites usually nega-
tively impacts patients’ quality of life [32]. Although
patients’ clinical outcomes cannot be altered, and the es-
timated survival time is limited, symptoms relief should
be the treatment goal for these advanced non-ovarian
cancer patients with MA. As the disease advanced and
symptoms worsened, the refractory ascites dramatically
exacerbated several symptoms of patients with terminal
malignancies [10]. Paracentesis was testified to relieve
these symptoms in 90 % of patients [45]. In our study,
all the patients experienced benefits in the form of at
least one symptom relieved. The abdominal swelling,
anorexia, and constipation were relieved significantly. In
fact, symptoms were implicative of each other. For in-
stance, untreated abdominal swelling could lead to nau-
sea, pain, constipation, dyspnea and vice versa. But the
symptom alleviation was not satisfactory. Some symp-
toms’ burden had little change despite the effective
removal of large volumes of abdominal fluid. The multi-
factorial causes of the symptoms may explain this
observation.
Limitations of this study include selection bias due to
the retrospective nature of the study and a small sample
size. Further well powered randomized controlled stud-
ies should be conducted to analyze the influence of the
use of diuretics, which was used based on each patient’s
specific circumstances. Further prospective and random-
ized studies should be conducted to examine the use of
diuretics with paracentesis in the management of MA
and to clarify the effect of diuretic usage in MA patients
with indwelling catheters for drainage. Prospective stud-
ies focused on the combination of efficacy, symptoms
improvement assessment, survival length, and patient
satisfaction will help to describe the role of indwelling
catheters in patients with advanced cancer with MA.
Conclusion
Our study retrospectively detailed the care of 78 advanced
non-ovarian cancer patients with MA. Paracentesis and in-
dwelling catheter drainage through CVC set was a useful
method to improve symptom sufferings. Future research is
needed to validate these findings.
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